Pharma Deadline Extended: Govt Grants Relief to Small & Medium Firms

The Ministry of Health & Family Welfare has given three months from February 11, 2025, to the small and medium pharmaceutical firms to submit their plan for upgradation to the central license approving authority in order to be eligible to qualify for Schedule M deadline extension, the ministry said in a release.

The ministry further said it has conditionally extended the due date for implementation of revised Schedule M, the good manufacturing practices provision, in respect of small and medium manufacturers having turnover of Rs 250 crore or less, up to December 31, 2025.

On December 28, 2023, the Centre notified revised ‘Schedule M’ requirements wherein “good manufacturing practices” was upgraded to “good manufacturing practices and requirements of plan and equipment for pharmaceutical products”.

Under this, manufacturers were divided into two groups with the first category of large manufacturers having turnover more than Rs 250 crore. A timeline of six months was given to such manufacturers for compliance and the revised Schedule M requirements have been implemented for these manufacturers from June 28, 2024.

For small and medium manufacturers with turnover less than or equal to Rs 250 crore, a timeline of 12 months was given for compliance.

“Small and medium manufacturers had represented for extension of timeline to enable improvement in infrastructure, training of personnel and arranging financial resources,” the ministry said.

It added, “The same has been considered and the small and medium manufacturers have been given a time of three months from February 11, 2025, to submit their plan for upgradation in Form A to the Central License Approving Authority. For such manufacturers who submit these details, the timeline of implementation would be extended till December 31, 2025.”

The revised Schedule M requirements are a positive step towards ensuring the quality and safety of pharmaceutical products being manufactured in India, the ministry said.

The new regulations would enable the pharma companies to not only strengthen their domestic position but also become more competitive globally, it added.

Source: PTI

Related Posts

Green or red dot? Your soap, shampoo and toothpaste will now reveal if they’re veg or non-veg

Green dot or red dot? Soaps, shampoos and toothpaste to reveal if they are veg or non-veg That green dot you usually look for on a food packet could soon…

Counterfeit rabies vaccine worth ₹2 lakh seized in Delhi

The Drugs Control Department has seized counterfeit rabies vaccine worth about ₹2 lakh from a firm in Chandni Chowk’s Bhagirath Palace, the Delhi government said on Tuesday. Health Minister Pankaj…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Green or red dot? Your soap, shampoo and toothpaste will now reveal if they’re veg or non-veg

Green or red dot? Your soap, shampoo and toothpaste will now reveal if they’re veg or non-veg

Counterfeit rabies vaccine worth ₹2 lakh seized in Delhi

Counterfeit rabies vaccine worth ₹2 lakh seized in Delhi

AIIA organises public awareness rally on 11th Ayurveda Day

AIIA organises public awareness rally on 11th Ayurveda Day

UKHSA and University of Oxford scientists uncover genetic changes in the bacteria causing severe Kent meningococcal disease outbreak

UKHSA and University of Oxford scientists uncover genetic changes in the bacteria causing severe Kent meningococcal disease outbreak

‘Broad daylight dacoity’, says Supreme Court on overpricing of essential cancer drugs

‘Broad daylight dacoity’, says Supreme Court on overpricing of essential cancer drugs

CDSCO finds one spurious drug sample in Delhi, 220 NSQs in Aug surveillance

CDSCO finds one spurious drug sample in Delhi, 220 NSQs in Aug surveillance